Safety of 90Y-ibritumomab Tiuxetan Treatment for Japanese Patients in Real-world Clinical Practice.

In conclusion, we showed that hematotoxicity is a major adverse event of 90Y-IT treatment and that the nadir time is later than that with conventional anticancer agents. Medical staff, including pharmacists, should direct attention to the initial symptoms of hematotoxicity, especially in those patients who have received several prior regimens.
PMID: 30606920 [PubMed - in process]

Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - January 6, 2019 Category: Drugs & Pharmacology Authors: Yoshikawa H, Sakurashita H, Izumitani S, Taogoshi T, Saeki Y, Matsuo H Tags: Yakugaku Zasshi Source Type: research